Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$20.91 ▲ +0.26
(+1.26%)
MKT CAP: $1.24B • VOL: 968.3K
52W L $7 52W H $26
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$23
MEAN
$24
HIGH
$28
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VOR TAPE
VOR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $25.30 | $24.05 | 2025-02-14 | $19.03 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $26.35 | $24.67 | 2025-02-06 | $19.66 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $23.84 | $23.00 | 2025-01-29 | $20.07 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $21.33 | — | 2025-01-17 | $20.49 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.40 | $19.86 | 2025-01-09 | $18.61 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $24.88 | $21.75 | 2024-12-18 | $18.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $20.28 | $21.12 | 2024-12-04 | $19.45 | -4.3% | 48% | C |